|
CD19x22 CAR T cell therapy and severe ICANS: it’s been a bumpy ride |
04/08/2025 - 8:45am to 9:30am MDT |
|
Childhood ALL: What now and what does it mean for Transplant as we know it? |
07/08/2025 - 8:45am to 9:30am MDT |
|
Emapalumab therapy for hemophagocytic lymphohistiocytosis before reduced-intensity transplantation improves chimerism |
01/28/2025 - 8:45am to 9:30am MST |
|
Establishing Multidisciplinary Frameworks for CMV Prevention and Treatment in High-Risk Posttransplant Patients |
04/29/2025 - 2:45am to 3:30am MDT |
|
Fellow Journal Club: Project EVOLVE |
11/18/2025 - 8:45am to 9:30am MST |
|
First Fill-Up: Early Results from the REFUEL Trial |
11/25/2025 - 8:45am to 9:30am MST |
|
From Microbes to Medicine: My Path in Pediatric BMT and Advancing Equity in Pediatric Cancer |
02/04/2025 - 8:45am to 9:30am MST |
|
GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity |
05/13/2025 - 8:45am to 9:30am MDT |
|
GVHD: The Good, The Bad, and the Very Bad |
07/15/2025 - 8:45am to 9:30am MDT |
|
Haplo BMT for SCD - BMT CTN Outcomes |
07/01/2025 - 8:45am to 9:30am MDT |
Facebook
X
LinkedIn
Forward